Daniella Beckman
Former Chief Financial Officer
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Daniella Beckman
Tango Therapeutics, Inc. reported in an 8-K filed May 8, 2026 that Daniella Beckman was terminated as Chief Financial Officer, principal accounting officer and principal financial officer, effective April 15, 2026. The proxy statement of Tango Therapeutics, Inc. reports total compensation of $1,155,775 for Daniella Beckman in fiscal 2025, including a base salary of $502,877. Disclosed compensation is on record for 6 fiscal years.
“the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Tango Therapeutics, Inc. (TNGX) | Former Chief Financial Officer | $502,877 | $1,155,775 |
| 2024 | Tango Therapeutics, Inc. (TNGX) | Former Chief Financial Officer | $486,314 | $3,166,290 |
| 2023 | Tango Therapeutics, Inc. (TNGX) | Former Chief Financial Officer | $441,777 | $1,522,744 |
| 2022 | Tango Therapeutics, Inc. (TNGX) | Chief Financial Officer | $425,100 | $1,516,879 |
| 2021 | Tango Therapeutics, Inc. (TNGX) | Chief Financial Officer | $377,945 | $3,176,664 |
| 2020 | Tango Therapeutics, Inc. (TNGX) | Chief Financial Officer | $323,447 | $834,374 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.